Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102531 | 0.91 | TP53 (0.52) | KDM4EALDH1A1 | |
| SCHEMBL5715171 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1MEN1KMT2APHGDH | |
| SCHEMBL5715479 | 0.90 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5714683 | 0.90 | SIGMAR1 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL5715401 | 0.90 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2APHGDH | |
| SCHEMBL6102884 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL5714291 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1 | |
| SCHEMBL5714979 | 0.88 | KDM4E (0.55) | KDM4EALDH1A1MEN1KMT2APHGDH | |
| SCHEMBL5714630 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6102224 | 0.86 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2APHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | KDM4E 1090/4885ALDH1A1 1504/4885MEN1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.